Akebia Therapeutics (AKBA) EPS (Basic) Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) EPS (Basic) Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -301.82% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.21% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -17.09% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 13.91% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 31.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 388.06% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -3,612.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,612.34% |
| Mar 31, 2026 | -230.63% |
| Dec 31, 2025 | 55.96% |
| Sep 30, 2025 | 102.14% |
| Jun 30, 2025 | 102.30% |
| Mar 31, 2025 | 129.58% |
| Dec 31, 2024 | -3,400.59% |
| Sep 30, 2024 | -23.81% |
| Jun 30, 2024 | 31.57% |
| Mar 31, 2024 | 39.67% |
| Dec 31, 2023 | 114.52% |
| Sep 30, 2023 | 73.85% |
| Jun 30, 2023 | -137.28% |
| Mar 31, 2023 | 58.87% |
| Dec 31, 2022 | 94.51% |
| Sep 30, 2022 | 14.14% |
| Jun 30, 2022 | 131.16% |
| Mar 31, 2022 | 19.58% |
| Dec 31, 2021 | 35.67% |
| Sep 30, 2021 | 18.10% |